OPNT logo

Opiant Pharmaceuticals (OPNT) Cash From Operations

OPNT Annual CFO

$1.93 M
+$3.96 M+194.96%

31 December 2021

1-Year Change

+194.96%
OPNT annual cash flow from operations is up +194.96% year-on-year

3-Year Change

+468.36%
OPNT annual cash flow from operations is up +468.36% over the past 3 years

All-time High

$5.56 M
OPNT annual cash flow from operations is currently -65.33% below its historical high of $5.56 million

Annual CFO Formula

Net Income + Non Cash Expenses + Changes In Working Capital
Annual CFI-$15.01 M
OPNT annual cash flow from investing activities is -$15.01 million
Annual CFF$2.72 M
OPNT annual cash flow from financing activities is $2.72 million
Annual FCF$1.93 M
OPNT annual free cash flow is $1.93 million

OPNT Cash From Operations Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

OPNT Quarterly CFO

-$4.74 M
+$5.88 M+55.39%

30 September 2022

1-Year Change

-1755.13%
OPNT quarterly cash flow from operations is down -1755.13% year-on-year

3-Year Change

-556.64%
OPNT quarterly cash flow from operations is down -556.64% over the past 3 years

All-time High

$11.91 M
OPNT quarterly cash flow from operations is currently -139.82% below its historical high of $11.91 million
Quarterly CFI-$411.10 K
OPNT quarterly cash flow from investing activities is -$411.10 thousand
Quarterly CFF$402.60 K
OPNT quarterly cash flow from financing activities is $402.60 thousand
Quarterly FCF-$5.15 M
OPNT quarterly free cash flow is -$5.15 million

OPNT Quarterly CFO Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

OPNT TTM CFO

-$15.47 M
-$5.03 M-48.15%

30 September 2022

1-Year Change

-804.03%
OPNT TTM cash flow from operations is down -804.03% year-on-year

3-Year Change

-480.55%
OPNT TTM cash flow from operations is down -480.55% over the past 3 years

All-time High

$11.05 M
OPNT TTM cash flow from operations is currently -239.95% below its historical high of $11.05 million
TTM CFI$14.63 M
OPNT TTM cash flow from investing activities is $14.63 million
TTM CFF$1.19 M
OPNT TTM cash flow from financing activities is $1.19 million
TTM FCF-$15.88 M
OPNT TTM free cash flow is -$15.88 million

OPNT TTM CFO Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

OPNT Cash From Operations Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+195.0%-1755.1%-804.0%
3 y3 years+468.4%-556.6%-480.6%
5 y5 years+150.2%-388.7%-480.6%

OPNT Cash From Operations High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year
5 y5-year
alltimeall time-65.3%-139.8%-240.0%

Opiant Pharmaceuticals Cash From Operations History

DateAnnualQuarterlyTTM
Sept 2022
-
-$4.74 M(-55.4%)
-$15.47 M(+48.2%)
June 2022
-
-$10.63 M(+405.2%)
-$10.44 M(+452.5%)
Mar 2022
-
-$2.10 M(-205.0%)
-$1.89 M(-198.1%)
Dec 2021
$1.93 M(-195.0%)
$2.00 M(+599.6%)
$1.93 M(-212.6%)
Sept 2021
-
$286.40 K(-113.8%)
-$1.71 M(+8.6%)
June 2021
-
-$2.08 M(-221.2%)
-$1.58 M(+37.5%)
Mar 2021
-
$1.71 M(-204.8%)
-$1.15 M(-43.5%)
Dec 2020
-$2.03 M(-149.9%)
-$1.63 M(-487.5%)
-$2.03 M(-131.4%)
Sept 2020
-
$421.60 K(-125.6%)
$6.46 M(+21.5%)
June 2020
-
-$1.65 M(-298.4%)
$5.32 M(-16.1%)
Mar 2020
-
$830.00 K(-87.9%)
$6.34 M(+56.0%)
Dec 2019
$4.06 M(-877.0%)
$6.86 M(-1050.0%)
$4.06 M(-234.9%)
Sept 2019
-
-$721.90 K(+15.3%)
-$3.01 M(-8.0%)
June 2019
-
-$626.00 K(-56.7%)
-$3.27 M(-21.5%)
Mar 2019
-
-$1.45 M(+563.5%)
-$4.17 M(+697.2%)
Dec 2018
-$523.00 K(-86.4%)
-$218.00 K(-77.8%)
-$523.00 K(+71.5%)
Sept 2018
-
-$983.00 K(-35.4%)
-$305.00 K(+4.5%)
June 2018
-
-$1.52 M(-169.2%)
-$292.00 K(-81.5%)
Mar 2018
-
$2.20 M(-326.8%)
-$1.58 M(-132.3%)
Dec 2017
-$3.84 M(-169.1%)
-
-
Oct 2017
-
-$970.00 K(-65.5%)
$4.88 M(-12.1%)
July 2017
$5.56 M(-707.0%)
-$2.81 M(-13.5%)
$5.56 M(-17.3%)
Apr 2017
-
-$3.25 M(-127.3%)
$6.72 M(-39.2%)
Jan 2017
-
$11.91 M(-4122.1%)
$11.05 M(-2485.6%)
Oct 2016
-
-$296.00 K(-82.0%)
-$463.20 K(-49.4%)
July 2016
-$915.30 K(-78.4%)
-$1.65 M(-251.4%)
-$915.40 K(+116.5%)
Apr 2016
-
$1.09 M(+177.7%)
-$422.80 K(-81.0%)
Jan 2016
-
$392.00 K(-152.4%)
-$2.22 M(-44.7%)
Oct 2015
-
-$748.20 K(-35.2%)
-$4.01 M(-5.3%)
July 2015
-$4.24 M
-$1.16 M(+62.7%)
-$4.24 M(+24.0%)
Apr 2015
-
-$709.70 K(-49.3%)
-$3.42 M(+15.9%)
Jan 2015
-
-$1.40 M(+43.8%)
-$2.95 M(+73.0%)
DateAnnualQuarterlyTTM
Oct 2014
-
-$974.00 K(+191.6%)
-$1.70 M(+69.5%)
July 2014
-$1.01 M(+34.5%)
-$334.00 K(+39.4%)
-$1.01 M(-122.9%)
Apr 2014
-
-$239.60 K(+52.8%)
$4.39 M(-644.5%)
Jan 2014
-
-$156.80 K(-43.0%)
-$806.10 K(-1.3%)
Oct 2013
-
-$274.90 K(-105.4%)
-$816.50 K(+9.3%)
July 2013
-$747.30 K(-31.9%)
$5.06 M(-193.1%)
-$747.30 K(-87.9%)
Apr 2013
-
-$5.43 M(+3150.4%)
-$6.16 M(+588.4%)
Jan 2013
-
-$167.20 K(-18.7%)
-$894.30 K(+14.7%)
Oct 2012
-
-$205.70 K(-41.1%)
-$779.50 K(-28.9%)
July 2012
-$1.10 M(-62.9%)
-$349.00 K(+102.4%)
-$1.10 M(+26.5%)
Apr 2012
-
-$172.40 K(+229.0%)
-$867.20 K(-71.2%)
Jan 2012
-
-$52.40 K(-90.0%)
-$3.01 M(-8.4%)
Oct 2011
-
-$522.90 K(+337.6%)
-$3.29 M(+11.2%)
July 2011
-$2.96 M(+680.7%)
-$119.50 K(-94.8%)
-$2.96 M(+2.5%)
Apr 2011
-
-$2.31 M(+602.1%)
-$2.88 M(+291.4%)
Jan 2011
-
-$329.70 K(+71.7%)
-$736.60 K(+29.0%)
Oct 2010
-
-$192.00 K(+310.3%)
-$571.00 K(+50.8%)
July 2010
-$378.60 K(<-9900.0%)
-$46.80 K(-72.2%)
-$378.60 K(+14.2%)
Apr 2010
-
-$168.10 K(+2.4%)
-$331.50 K(+102.8%)
Jan 2010
-
-$164.10 K(<-9900.0%)
-$163.50 K(<-9900.0%)
Oct 2009
-
$400.00(+33.3%)
$700.00(+600.0%)
July 2009
$100.00(-200.0%)
$300.00(-400.0%)
$100.00(-99.1%)
Apr 2009
-
-$100.00(-200.0%)
$10.60 K(+12.8%)
Jan 2009
-
$100.00(-150.0%)
$9400.00(>+9900.0%)
Oct 2008
-
-$200.00(-101.9%)
$0.00(0.0%)
July 2008
-$100.00(-99.7%)
$10.80 K(-930.8%)
$0.00(-100.0%)
Apr 2008
-
-$1300.00(-86.0%)
-$14.50 K(-38.8%)
Jan 2008
-
-$9300.00(+4550.0%)
-$23.70 K(+5.3%)
Oct 2007
-
-$200.00(-94.6%)
-$22.50 K(-26.7%)
July 2007
-$30.60 K
-$3700.00(-64.8%)
-$30.70 K(+13.7%)
Apr 2007
-
-$10.50 K(+29.6%)
-$27.00 K(+63.6%)
Jan 2007
-
-$8100.00(-3.6%)
-$16.50 K(+96.4%)
Oct 2006
-
-$8400.00
-$8400.00

FAQ

  • What is Opiant Pharmaceuticals annual cash flow from operations?
  • What is the all time high annual CFO for Opiant Pharmaceuticals?
  • What is Opiant Pharmaceuticals annual CFO year-on-year change?
  • What is Opiant Pharmaceuticals quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Opiant Pharmaceuticals?
  • What is Opiant Pharmaceuticals quarterly CFO year-on-year change?
  • What is Opiant Pharmaceuticals TTM cash flow from operations?
  • What is the all time high TTM CFO for Opiant Pharmaceuticals?
  • What is Opiant Pharmaceuticals TTM CFO year-on-year change?

What is Opiant Pharmaceuticals annual cash flow from operations?

The current annual CFO of OPNT is $1.93 M

What is the all time high annual CFO for Opiant Pharmaceuticals?

Opiant Pharmaceuticals all-time high annual cash flow from operations is $5.56 M

What is Opiant Pharmaceuticals annual CFO year-on-year change?

Over the past year, OPNT annual cash flow from operations has changed by +$3.96 M (+194.96%)

What is Opiant Pharmaceuticals quarterly cash flow from operations?

The current quarterly CFO of OPNT is -$4.74 M

What is the all time high quarterly CFO for Opiant Pharmaceuticals?

Opiant Pharmaceuticals all-time high quarterly cash flow from operations is $11.91 M

What is Opiant Pharmaceuticals quarterly CFO year-on-year change?

Over the past year, OPNT quarterly cash flow from operations has changed by -$5.03 M (-1755.13%)

What is Opiant Pharmaceuticals TTM cash flow from operations?

The current TTM CFO of OPNT is -$15.47 M

What is the all time high TTM CFO for Opiant Pharmaceuticals?

Opiant Pharmaceuticals all-time high TTM cash flow from operations is $11.05 M

What is Opiant Pharmaceuticals TTM CFO year-on-year change?

Over the past year, OPNT TTM cash flow from operations has changed by -$13.75 M (-804.03%)